Conférences
le (13m7s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 471
Conférences
le (52m37s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)
... final position yet. Implementation of adaptive designs requires early and in-depth interaction between the agencies and study sponsors.➢ With the newer anti-thrombotic agents progressively potentially replacing warfarin, we are moving from a target INR... Voir la vidéo
Conférences
le (9m33s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)
... final position yet. Implementation of adaptive designs requires early and in-depth interaction between the agencies and study sponsors.➢ With the newer anti-thrombotic agents progressively potentially replacing warfarin, we are moving from a target INR... Voir la vidéo
Conférences
le (7m9s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joerg KOGLIN)
... final position yet. Implementation of adaptive designs requires early and in-depth interaction between the agencies and study sponsors.➢ With the newer anti-thrombotic agents progressively potentially replacing warfarin, we are moving from a target INR... Voir la vidéo
Label UNT Conférences
le (14m54s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
... control) and reduces cardiovascular risk. The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the... Voir la vidéo
Label UNT Conférences
le (11m50s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
... requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new agents, fail to emphasize the need to show clinical benefits, such as less visual impairment, less need for dialysis, or fewer... Voir la vidéo
Label UNT Conférences
le (19m17s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates).
... to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new agents, fail to emphasize the need to show clinical benefits, such as less visual impairment,... Voir la vidéo
Label UNT Conférences
le (13m24s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
... cardiovascular risk. The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new... Voir la vidéo
Label UNT Conférences
le (9m46s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
... cardiovascular risk. The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new... Voir la vidéo
Label UNT Conférences
le (44m48s)
